Everest Medicines (Beijing) Co., Ltd.
1952 · HKEX
Public Market Listing
Live quotes, historical charts, and market capitalization for Everest Medicines (Beijing) Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(7 total)
| Target & Modality | |||
|---|---|---|---|
Budesonide (targeted-release)(TARPEYO / Nefecon) | Approved | Glucocorticoid receptorSmall molecule | IgA Nephropathy |
etrasimod(Velsipity) | Approved | S1P receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis |
Lerodalcibep(Lerochol) | Phase 3 | PCSK9Protein / enzyme therapeutic | Atherosclerotic Cardiovascular Disease |
| Phase 3 | CaSR; OGPPeptide | Chronic Kidney Disease Secondary Hyperparathyroidism | |
| Phase 3 | CD20Monoclonal antibody | Systemic Lupus ErythematosusFollicular LymphomaPrimary Membranous Nephropathy | |
| Phase 3 | P2Y12 platelet receptorSmall molecule | Atherosclerotic Cardiovascular Disease | |
| Phase 1/2 | Multiple tumor-associated antigensVaccine | Non-Small Cell Lung Cancer |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
November 2026 (1)
December 2026 (1)
What to watch
2028 (2)
2029 (3)
2030 (1)
September 2030 (1)
What to watch
2031 (1)
July 2031 (1)
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
No financial reports recorded.